ID   SK-MEL-39
AC   CVCL_6036
SY   SK-Mel-39; SK-Mel 39; SK Mel 39; Sk Mel39; SKMEL-39; BF-Mel
DR   cancercelllines; CVCL_6036
DR   Cosmic; 706098
DR   Cosmic; 851042
DR   Cosmic; 888840
DR   Cosmic; 897487
DR   Cosmic; 933138
DR   Cosmic; 1669152
DR   Wikidata; Q54954136
RX   DOI=10.1007/978-1-4615-7228-2_39;
RX   PubMed=1067619;
RX   PubMed=3518877;
RX   PubMed=9598804;
RX   PubMed=9692547;
RX   PubMed=10766161;
RX   PubMed=15009714;
RX   PubMed=21725359;
RX   PubMed=24576830;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714; PubMed=21725359; PubMed=24576830).
CC   Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Unspecified (PubMed=9692547).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys183fs*7 (c.546_547insA); Zygosity=Unspecified (PubMed=9692547; PubMed=10766161).
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 23
//
RX   DOI=10.1007/978-1-4615-7228-2_39;
RA   Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Malignant melanoma. Current status of the search for melanoma-specific
RT   antigens.";
RL   (In) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston (1981).
//
RX   PubMed=1067619; DOI=10.1073/pnas.73.9.3278;
RA   Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F.,
RA   Old L.J.;
RT   "Cell surface antigens of human malignant melanoma: mixed
RT   hemadsorption assays for humoral immunity to cultured autologous
RT   melanoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//
RX   PubMed=9692547; DOI=10.1038/sj.onc.1201881;
RA   Tsao H., Zhang X., Benoit E., Haluska F.G.;
RT   "Identification of PTEN/MMAC1 alterations in uncultured melanomas and
RT   melanoma cell lines.";
RL   Oncogene 16:3397-3402(1998).
//
RX   PubMed=10766161;
RA   Tsao H., Zhang X., Fowlkes K., Haluska F.G.;
RT   "Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous
RT   melanoma cell lines.";
RL   Cancer Res. 60:1800-1804(2000).
//
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250;
RA   Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M.,
RA   She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I.,
RA   Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G.,
RA   Wolchok J.D., Houghton A.N., Solit D.B.;
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//